Relamorelin

Trial

ClassGHSR agonist

Typical routes in papersSC in trials

Half-life contextShort-acting trial designs

EvidenceDiabetic gastroparesis trials

What it is

Relamorelin is a ghrelin-receptor agonist aimed at making a sluggish stomach move — diabetic gastroparesis research.

Benefits in plain language

What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.

Hoped-for benefit: less vomiting and faster gastric emptying in diabetic stomach paralysis.
Hunger and GH bumps are on-family effects, but motility is the design target.
Not a first-line fat-loss tool.

If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.

Mechanism of action

GHSR agonism in gut-brain motor circuits accelerates gastric emptying.

Possible side effects / caveats

Hyperglycemia, hunger, GI cramping. Development status should be checked current.

Protocol ranges

Source tier	Amount	Frequency / duration	Notes
Trial examples	10–100 mcg class SC in papers	Often 1–2× daily	Gastroparesis programs

Numbers below and above are literature or community pointers, not a treatment plan. Approved products, when they exist, follow the official label — not a research vial.